Blood filtering for severe liver failure with organ damage
Part of Digestive system clinical trials.
This study tests a blood-filtering system called CytoSorb in people with severe liver failure that also affects other organs. It aims to see if removing toxins from the blood can help reduce damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a long-term liver condition (like cirrhosis) that suddenly got worse and requires hospital care.
- At least two major organs (such as kidneys, brain, or lungs) are failing because of your liver problem.
- You are age 18 or older.
- You will receive a special blood-filtering treatment called CytoSorb to remove harmful toxins.
- You have not had a sudden, severe liver failure without prior liver disease.
- You do not have advanced heart failure, a recent heart attack, or a severely weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a procedure that filters harmful substances from your blood using a special machine. It is for people with severe liver failure (acute-on-chronic) who have signs of inflammation throughout the body.
This trial tests whether removing and replacing blood plasma (a blood-cleaning procedure) can help people with sudden, severe liver failure recover. The treatment aims to support the liver while it heals or while waiting for a transplant.
This trial tests a new liver dialysis device called DIALIVE 2.0 for people with acute-on-chronic liver failure (a sudden, severe worsening of chronic liver disease). If you qualify, the device will help filter your blood, similar to kidney dialysis, to support your liver while it tries to recover.
This trial is testing new scoring systems to better predict how patients with acute-on-chronic liver failure will do. It may help doctors make more informed treatment decisions for people with this serious liver condition.
This trial tests a device called CytoSorb that filters the blood to reduce inflammation in patients with sudden worsening of chronic liver disease. It may help support organ function and recovery.
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
Hear when a new Acute on Chronic Liver Failure (ACLF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.